Qure.ai Continues Pace of US Growth With 19th FDA Clearance

Carbonatix Pre-Player Loader

Audio By Carbonatix

NEW YORK--(BUSINESS WIRE)--Oct 22, 2025--

Qure.ai, a TIME100 most influential company and global leader in digital healthcare, today announced its latest (510) K clearance from the US Food and Drug Administration (FDA). This milestone represents ongoing momentum in Qure.ai’s USA growth strategy and highlights its ongoing ability to deliver rigorously validated solutions that integrate seamlessly into hospital and clinical workflows to enhance patient outcomes.

The newly cleared solution, qER-CTA, is designed to assist clinicians by analyzing CT angiography (CTA) scans for suspected large vessel occlusions (LVOs) in the brain, which if untreated could cause an ischemic stroke. The solution can review internal carotid artery (ICA) and M1 segment of the middle cerebral artery (MCA) in adults (≥22 years), enabling faster triage and specialist notification in emergency care scenarios.

This clearance expands the Qure.ai FDA cleared portfolio in neurocritical findings and early cancer detection, reflecting the company’s ability to deliver clinically proven tools across multiple domains of care. It builds on a suite of AI solutions for neurocritical conditions in acute care, including the triage of intracranial haemorrhages and other critical brain emergencies. Qure.ai also continues to drive progress in its FDA cleared lung cancer solutions underscoring its commitment to improving both time-critical and long-term outcomes.

“This FDA clearance is another proof point of how Qure.ai is setting the standard for clinically validated AI that US clinicians can trust to improve patient outcomes,” said Jim Mercadante, Chief Commercial Officer at Qure.ai. “By combining our strengths in acute neurocritical care with advances in early lung cancer detection, we are showing how AI can be seamlessly integrated into clinical workflows to support healthcare professionals in both time-sensitive emergencies and long-term disease management.”

Dr Ajith Thomas, Chairman, Department of Neurosurgery at Cooper University Healthcare states, “FDA clearances for AI algorithms like this represent an encouraging step toward deeper AI adoption in clinical practice. The qER-CTA algorithm's ability to triage Large Vessel Occlusions will complement existing AI tools for critical CT findings. This integration promises to fundamentally change traditional workflows, significantly reducing time to treatment in emergency scenarios and strengthening clinical decision-making. If left unidentified, LVOs can rapidly cause ischemic strokes, leading to devastating disability and mortality without timely intervention. AI's capacity to flag potential occlusions, support rapid triage, and notify specialists sooner has the meaningful potential to dramatically improve patient outcomes."

Over the past several years, Qure.ai has built an unmatched portfolio of global approvals, with 19 FDA cleared findings, over 65 CE certified indications, and other national validations across its solutions. Deployed in over 105 countries across 4800+ sites, Qure.ai is touching more than 34 million lives. This milestone further strengthens its position as the most regulatory-approved AI provider in healthcare imaging and reinforces its commitment to building clinically validated tools that empower healthcare professionals in time-critical decision making.

About Qure.ai

Qure.ai is a global health tech company that innovates AI-enabled healthcare solutions to drive early clinical diagnosis and boost seamless patient care coordination. Qure's solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare workers or health systems by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.

Qure.ai has deployments in over 100 countries, with regional offices in New York, London, Dubai and Mumbai. It is a TIME100 Most Influential Company 2025.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251021229655/en/

CONTACT: For media queries:

Amrutha Joseph [email protected]| Georgina Wright [email protected]

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: TECHNOLOGY FDA NEUROLOGY HOSPITALS HEALTH TECHNOLOGY SOFTWARE HEALTH ARTIFICIAL INTELLIGENCE ONCOLOGY

SOURCE: Qure.ai

Copyright Business Wire 2025.

PUB: 10/22/2025 09:00 AM/DISC: 10/22/2025 08:59 AM

http://www.businesswire.com/news/home/20251021229655/en

 

Trending Videos

Salem News Channel Today

Sponsored Links

Trending Videos

On Air & Up Next

  • Best Stocks Now
    12:00PM - 1:00PM
     
    Bill Gunderson provides listeners with financial guidance that is both   >>
     
  • Bloomberg Businessweek
    1:00PM - 2:00PM
     
    Get the latest news from the world of business and finance and the interesting   >>
     
  • Money Pulse
    2:00PM - 2:30PM
     
    Host Dynasti Young and Craig Roberts talk to innovative startups and enduring businesses here in the Bay Area.
     
  • Business By The Bay
    2:30PM - 3:00PM
     
    San Francisco Bay Area has given the world some of the greatest business   >>
     
  • Investor's Edge
    3:00PM - 4:00PM
     
    Gary Kaltbaum is a hard hitting and pull-no-punches host especially when it   >>
     

See the Full Program Guide